文献速递瓣膜外科

孤立性二尖瓣心内膜炎的外科治疗:16年单中心经验

Surgical treatment for isolated mitral valve endocarditis: a 16-year single-centre experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

回顾性分析2000年1月至2015年12月128例孤立性二尖瓣心内膜炎患者的140次手术,其中自体瓣膜109次(78%)、人工瓣膜31次(22%)。30天死亡13例(9%),瓣膜修复76次(54%)30天死亡率1%,瓣膜置换64次(46%)30天死亡率19%。年龄、糖尿病、EuroSCORE II和瓣周脓肿是长期死亡的独立预测因素。

要点

  • 140次手术中30天死亡13例(9%),严重围术期并发症59例(42%)。
  • 瓣膜修复76次(54%)30天死亡率1%,5年和10年累积生存率分别为86±4%和77±6%。
  • 瓣膜置换64次(46%)30天死亡率19%,5年和10年累积生存率分别为55±7%和41±8%。

核心结论

  • 需外科治疗的二尖瓣心内膜炎是挑战性疾病,瓣膜置换后院内死亡率高。
  • 对合适的感染性心内膜炎患者可行二尖瓣修复,结果优良。
  • 多变量模型中年龄、糖尿病和EuroSCORE与死亡率独立相关。

研究设计与样本

  • 回顾性研究,纳入2000年1月至2015年12月128例因二尖瓣心内膜炎行140次手术的患者。
  • 其中自体瓣膜心内膜炎109次(78%),人工瓣膜心内膜炎31次(22%)。
  • 登记术前和术后特征及死亡率,采用Cox回归识别与死亡率相关的因素。
  • 平均随访68个月(范围1-168个月),随访完整率100%。

主要发现

  • 140次手术后30天内死亡13例(9%),严重围术期并发症发生于59次(42%)手术。
  • 首次手术后总体累积生存率5年为73%±4,10年为62±5%。
  • 瓣膜修复76次(54%)30天死亡率为1%,5年和10年累积生存率分别为86±4%和77±6%。
  • 瓣膜置换64次(46%)30天死亡率为19%,5年和10年累积生存率分别为55±7%和41±8%。
  • 修复和置换术后并发症发生率分别为21%和67%。

关键数值与推荐

  • 年龄、糖尿病、EuroSCORE II和瓣周脓肿是长期死亡的独立预测因素。

临床怎么用

  • 对合适的感染性心内膜炎患者可行二尖瓣修复,作者报告其结果优良。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite progress in management, mitral valve endocarditis (MVE) is still a life-threatening disease. We report our experience in surgical treatment of infective isolated MVE. METHODS: A total of 140 operations in 128 patients for MVE performed between January 2000 and December 2015 were included in a retrospective study. There were 109 (78%) operations for native and 31 (22%) operations for prosthetic valve endocarditis. Preoperative and postoperative characteristics and mortality of patients were registered. Cox regression identified factors associated with mortality. Mean follow-up period was 68 months (range 1-168 months) and 100% complete. RESULTS: There were 13 deaths within 30 days after the 140 operations (9%). Severe perioperative complications occurred in 59 (42%) operations. Overall cumulative survival was 73% ± 4 at 5 years and 62 ± 5% at 10 years after the first operation. Age, diabetes, EuroSCORE II and perivalvular abscess were independent predictors for long-term mortality. Valve repair was performed in 76 (54%) operations and replacement in 64 (46%) operations. Thirty-day mortality for repair was 1%, and 5-year and 10-year cumulative survival was 86 ± 4% and 77 ± 6%, respectively. In the replacement group the 30-day mortality was 19% and cumulative survival at 5 years and 10 years was 55 ± 7% and 41 ± 8%, respectively. Postoperative complications occurred in 21% and 67%, respectively, after operations for repair and replacement. Ten (8%) patients had 12 reoperations for recurrent endocarditis. CONCLUSIONS: MVE requiring surgical treatment is a challenging disease with high hospital mortality after valve replacement. Mitral valve repair can be performed in suitable endocarditis patients with excellent results. Age, diabetes and EuroSCORE were independently associated with mortality in a multivariable model.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Perrotta S, Fröjd V, Lepore V, et al. Surgical treatment for isolated mitral valve endocarditis: a 16-year single-centre experience. Eur J Cardiothorac Surg. 2018. PMID: 29186533. doi:10.1093/ejcts/ezx416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。